Steinberg, Seth M.

Use of proteomic patterns in serum to identify ovarian cancer

Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., et al. (2002) · The Lancet

Ovarian cancer diagnosis and treatmentAdvanced Proteomics Techniques and Applications

Cited by 3,236

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 2,898

Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,575

Age, Thymopoiesis, and CD4+ T-Lymphocyte Regeneration after Intensive Chemotherapy

Mackall, C. L., Fleisher, T. A., Brown, M. R., Andrich, M. P., Chen, C. C., Feuerstein, I. M., Horowitz, M. E., Magrath, I. T., Shad, A. T., Steinberg, S. M., et al. (1995) · New England Journal of Medicine

T-cell and B-cell ImmunologyHematopoietic Stem Cell Transplantation

Cited by 1,026

Ten-Year Results of a Comparison of Conservation with Mastectomy in the Treatment of Stage I and II Breast Cancer

Jacobson, J. A., Danforth, D. N., Cowan, K. H., d'Angelo, T., Steinberg, S. M., Pierce, L., Lippman, M. E., Lichter, A. S., Glatstein, E., & Okunieff, P. (1995) · New England Journal of Medicine

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 892

Identification of essential genes for cancer immunotherapy

Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 870

Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 624

Eighteen‐year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: The National Cancer Institute randomized trial

Poggi, M. M., Danforth, D. N., Sciuto, L. C., Smith, S. L., Steinberg, S. M., Liewehr, D. J., Menard, C., Lippman, M. E., Lichter, A. S., & Altemus, R. M. (2003) · Cancer

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 569

CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T cell potency and toxicity: updated results from a phase I anti-CD22 CAR T cell trial

Shah, N. N., Highfill, S. L., Shalabi, H., Yates, B., Jin, J., Wolters, P. L., Ombrello, A., Steinberg, S. M., Martin, S., Delbrook, C., et al. (2020) · Journal of Clinical Oncology

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 421

Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial

Lopez-Chavez, A., Thomas, A., Rajan, A., Raffeld, M., Morrow, B., Kelly, R., Carter, C. A., Guha, U., Killian, K., Lau, C. C., et al. (2015) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 233

Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study

Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., et al. (2020) · Clinical Cancer Research

PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment

Cited by 220

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

Jeong, W., Rapisarda, A., Park, S. R., Kinders, R. J., Chen, A., Melillo, G., Turkbey, B., Steinberg, S. M., Choyke, P., Doroshow, J. H., et al. (2014) · Cancer Chemotherapy and Pharmacology

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 159

Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease

Polizzotto, M. N., Uldrick, T. S., Wang, V., Aleman, K., Wyvill, K. M., Marshall, V., Pittaluga, S., O’Mahony, D., Whitby, D., Tosato, G., et al. (2013) · Blood

Viral-associated cancers and disordersLymphadenopathy Diagnosis and Analysis

Cited by 158

Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study

Polizzotto, M. N., Uldrick, T. S., Wyvill, K. M., Aleman, K., Peer, C. J., Bevans, M., Sereti, I., Maldarelli, F., Whitby, D., Marshall, V., et al. (2016) · Journal of Clinical Oncology

Viral-associated cancers and disordersLymphoma Diagnosis and Treatment

Cited by 138

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors

Kummar, S., Raffeld, M., Juwara, L., Horneffer, Y., Strassberger, A., Allen, D., Steinberg, S. M., Rapisarda, A., Spencer, S. D., Figg, W. D., et al. (2011) · Clinical Cancer Research

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 115

Genetic Ablation of Epidermal EGFR Reveals the Dynamic Origin of Adverse Effects of Anti-EGFR Therapy

Mascia, F., Lam, G., Keith, C., Garber, C., Steinberg, S. M., Kohn, E., & Yuspa, S. H. (2013) · Science Translational Medicine

Chemotherapy-related skin toxicityHER2/EGFR in Cancer Research

Cited by 105

Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days

Mikkilineni, L., Yates, B., Steinberg, S. M., Shahani, S. A., Molina, J. C., Palmore, T., Lee, D. W., Kaplan, R. N., Mackall, C. L., Fry, T. J., et al. (2021) · Blood Advances

CAR-T cell therapy researchNeutropenia and Cancer Infections

Cited by 75

Liver resection and ablation for metastatic adrenocortical carcinoma

Ripley, R. T., Kemp, C. D., Davis, J. L., Langan, R. C., Royal, R. E., Libutti, S. K., Steinberg, S. M., Wood, B. J., Kammula, U. S., Fojo, T., et al. (2011) · Annals of Surgical Oncology

Adrenal and Paraganglionic TumorsRenal cell carcinoma treatment

Cited by 62

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease

Ramaswami, R., Lurain, K., Peer, C. J., Serquiña, A., Wang, V., Widell, A., Goncalves, P., Steinberg, S. M., Marshall, V., George, J., et al. (2020) · Blood

Viral-associated cancers and disordersCytomegalovirus and herpesvirus research

Cited by 51

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial

Kazandjian, D., Hill, E., Dew, A., Morrison, C., Roswarski, J., Korde, N., Emanuel, M., Petrosyan, A., Bhutani, M., Calvo, K. R., et al. (2021) · JAMA Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 49

RAG-Mediated V(D)J Recombination Is Not Essential for Tumorigenesis in Atm-Deficient Mice

Petiniot, L. K., Weaver, Z., Vacchio, M., Shen, R., Wangsa, D., Barlow, C., Eckhaus, M., Steinberg, S. M., Wynshaw-Boris, A., Ried, T., et al. (2002) · Molecular and Cellular Biology

DNA Repair MechanismsT-cell and B-cell Immunology

Cited by 40

Abstract CT268: Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: A phase I clinical trial

Abel, M. L., Takahashi, N., Desai, P., Peer, C., Redon, C., Nichols, S., Vilimas, R., Lee, M.-J., Lee, S., Sciuto, L., et al. (2023) · Cancer Research

Cancer therapeutics and mechanismsPARP inhibition in cancer therapy

Cited by 4